Replies to post #339619 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

OAG (0pen Angle Glaucoma) was found in 41 (23.8%) of the AD patients, which was a significantly (p = 0.0002) higher prevalence than that in the controls (9.9%).

https://pubmed.ncbi.nlm.nih.gov/16564058/

There are 509 participants in the Phase 2b/3 Blacamesine trial for those with early stage Alzheimer’s disease.

Therefore, there could be 23.8% of the 509 equates to approximately 121 of those 509 participants may also have glaucoma possibly at an early stage.

our study supports the idea that the sR1 is a promising therapeutic target for neurodegenerative retinal diseases, such as glaucoma.

https://pubmed.ncbi.nlm.nih.gov/21541278/

Therefore, since Blarcamesine activates the sigma 1 receptor, then treatment with Blarcamesine may have a positive responses in participants with both Alzheimer’s disease and glaucoma.

Good luck and GOD bless,

[chrismiss_everyday]

“ As I’ve projected previously, there is a very reasonable use of blarcamesine as drug agent that slows cellular and systematic aging, a Ponce de León anti-aging drug. With this, everyone in early middle age would take a few milligrams of blarcamesine, perhaps just two days a week. With that, the debilities (and profound costs and sufferings) of middle and old age are markedly reduced. Would anyone reject this therapy if it cost $20 a week (two $10 blarcamesine tablets), a cost of $1040 a year?”

I would TOTALLY pay $1040/ year for such a prophylaxis! That’s a no-brainer. :-)

[end2war]

I would not put to much faith in the idea that 2-72 is a magic elixir that will cure all ills, or that it is the latter-day version of The Myth of Ponce de León and the Fountain of Youth.

Regenerative medicine may someday arrive when they learn more about stem cells and genetics, but for now stimulating receptors that have evolved to have protective effects will in my opinion, at best, reduce some of the detrimental effects of disease and/or aging, one clinical trial at a time.

Personally, I will keep my eye on the science, one step at a time, and try not to count my chickens before they hatch. Rett syndrome is the next step.

[georgejjl]

falconer, I agree 100%.

Then, beyond Alzheimer’s.
Quote:
Yearly price for Blarcamesine treatment for Alzheimer's disease $3652.50

At a $10 per day treatment (drug) cost, this is the yearly cost. If blarcamesine proves it can both prevent continued progression and also reverse Alzheimer’s symptoms (safely, without the brain swelling induced by Aduhelm) there is no reason this can’t be a fair and equitable price; one that would be paid for by insurance. Who with Alzheimer’s can get cared for for just $3600 a year? It would be a bargain for any and all parties dealing with Alzheimer’s patients; government health programs, private health insurance companies, and the families with Alzheimer’s relatives.

Consequently, the numbers projected for Anavex Life Sciences are within reason.

Not enough data yet to make the following projections likely, but what happens when it is discovered (as I believe it will be) that those taking blarcamesine not only get their Parkinson’s or Alzheimer’s resolved, but at the same time they have significantly reduced frequencies of the many diseases and conditions afflicting people as they age? What if, at the first so incidentally, blarcamesine proves to prevent or reverse most of the other diseases caused by dyshomeostasis, dysfunction of cell maintenance, anomalous homeostasis?

As I’ve projected previously, there is a very reasonable use of blarcamesine as drug agent that slows cellular and systematic aging, a Ponce de León anti-aging drug. With this, everyone in early middle age would take a few milligrams of blarcamesine, perhaps just two days a week. With that, the debilities (and profound costs and sufferings) of middle and old age are markedly reduced. Would anyone reject this therapy if it cost $20 a week (two $10 blarcamesine tablets), a cost of $1040 a year?

Punch your own numbers on that scenario. More people get old than get Parkinson’s or Alzheimer’s.

In a few years might a holding of a number of AVXL shares be rewarding? In the scenario of blarcamesine approval for any of the three indications being clinically tested (Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s), Anavex Life Sciences Corp (and its shareholders) will be a success. But there are so many other potential, eventual applications for the company’s proprietary sigma-1 receptor agonists (activators). As I’ve contended, we are yet in the early chapters of the Anavex story. In a decade, the story will take several volumes; used as an historical reference text in business schools.

Good luck and GOD bless,

[Ortiz]

“What if, at the first so incidentally, blarcamesine proves to prevent or reverse most of the other diseases caused by dyshomeostasis, dysfunction of cell maintenance, anomalous homeostasis?”

Hopefully, somewhere in one of this scientific description of cellular homeostasis, DM2 is included.

IMO

[Steady_T]

I know people that spend $100/mo. or more on vitamins and supplements.

Even Relief Factor costs $80 to $93 per month. If 2-73 works as a general tonic and that is clinically demonstrated many people would buy that.

It will be quite a while before 2-73 becomes over the counter or available at that low price.

[tredenwater2]

In a decade, the story will take several volumes; used as an historical reference text in business schools.

Yes, I agree for those that can see past the nose on their face. Dr. Missling is not settling for one indication or even two. I get the feeling he has “several volumes” in story for this point in history. This IP is priceless as it stands right now, especially with the speed with which it is starting new indications.

My advice is to know what you own and make your own choices based on DD. I have and have done very well in the face of many people telling me just the opposite.

Cheers

Tred